Company Overview: Catalsyt

Industry News

11 Apr

Key Milestone Reached in Catalyst’s Subcutaneous Factor IX Program

SOUTH SAN FRANCISCO, Calif., April 11, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a key milestone under its collaboration with ISU Abxis to advance the Factor IX program towards...

Read more

3 Aug

Catalyst Biosciences to Present at Ophthalmology Innovation Summit

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, announced today an upcoming presentation describing progress in its complement factor 3 (C3) program at the Ophthalmology Innovation Summit...

Read more

2 Aug

Catalyst Biosciences Announces Agreement to Sell Three NNR Assets to Attenua

— Divestment of Certain Neuronal Nicotinic Receptor Assets to Provide Catalyst with $1 Million Up Front Payment — — Catalyst Remains Focused on Core Therapeutic Areas, Especially Hemophilia — SOUTH SAN FRANCISCO, Calif., Aug. 02, 2016 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on...

Read more

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address